CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 136 enrolled
Drug / intervention
NB medication (Naltrexone Bupropion combination) +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03045341
NCT03045341Phase 3Completed
CompareCT.gov

Behavioral and Pharmacologic Treatment of Binge Eating and Obesity

Yale University·interventional·Posted Feb 7, 2017·Updated Mar 8, 2023

In Brief

A Phase 3 clinical trial evaluating NB medication (Naltrexone Bupropion combination), Behavioral Weight Loss (BWL) counseling, and 1 other intervention for Binge-eating Disorder and Obesity. Completed, enrolled 136 participants across 1 site.

Detailed Summary

This study will test the effectiveness and relative efficacy of behavioral and pharmacologic treatments, alone and in combination, for the treatment of binge eating disorder (BED) in patients with obesity. This is an acute treatment comparing behavioral weight loss alone or in combination with naltrexone/bupropion medication.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBinge-eating Disorder, Obesity
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 7, 2017
Enrollment StartFeb 27, 2017
Primary CompletionJul 23, 2021
Study CompletionDec 16, 2022
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 9.4 years ago

Interventions

NB medication (Naltrexone Bupropion combination)drug

NB medication

Behavioral Weight Loss (BWL) counselingbehavioral

BWL counseling

Placeboother

Placebo